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Dual-agent chemotherapy is the current standard of care for patients 
with advanced non-small-cell lung cancer (NSCLC). While progress in 
patients’ outcome has been made, signiﬁcant variability in the efﬁcacy 
and toxicity of anticancer drugs is observed in unselected popula-
tions of patients. Recent studies have shown promise for improved 
outcome if therapy is selected based on molecular tumor character-
istics. Although resistance to gemcitabine and/or platinum are likely 
multifactorial, nucleotide metabolism and DNA repair have emerged 
as critical components. Previous studies have demonstrated a relation-
ship between RRM1 gene expression and differential sensitivity to 
gemcitabine/cisplatin. RRM1 is involved nucleotide metabolism and 
the nucleotide excision repair pathway, and up-regulation of this gene 
results in resistance to these agents.
Methods: We have generated three human cancer cell lines derived 
from lung, colon, and breast, with increased and decreased RRM1 
expression by stable transfection. The authenticity of cell lines was 
veriﬁed by genome typing. Chemosensitivity testing of different drugs 
was performed in vitro with the CellTiter-Glo® Luminescent cell vi-
ability assay.
Results: RRM1 expression at the mRNA and protein level was vari-
able among clones. For drug testing, clones with a greater than 2-fold 
increase (for up regulation) and a greater than 50% decrease (for down 
regulation) of RRM1 expression at the mRNA and protein level were 
selected. Scrambled sequence and out of frame RRM1 constructs were 
used to generate the control clones. When examining the associa-
tion between the expression of RRM1 and the IC50 of drugs, RRM1 
overexpressing clones showed resistance and underexpressing clones 
sensitivity to some drugs; most notably to gemcitabine.
Conclusions: Understanding the role of speciﬁc genes on DNA dam-
age repair and response to treatment is paramount to the evolving con-
cept of individualized chemotherapy. It is well known the efﬁcacy of 
various treatment regimens varies greatly among patients. Our in vitro 
RRM1 regulation model has the potential to not only help with tailor-
ing the clinical selection of chemotherapy but also with understanding 
the function of RRM1 in tumor biology.
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Background: Dendritic cells (DCs) are the most potent antigen-pre-
senting cells for initiating cellular immune response. Cancer-testis 
antigens (CTA) are the biggest tumor antigens family expressing only 
in some tumors and genital system but not in normal cells. XAGE-
1b gene is one of CTA which highly expresses in lung cancer and 
has strong immunogenicity. Our study was to examine whether DCs 
loaded with XAGE-1b protein could induce speciﬁc antitumor response 
against lung cancer cells in vitro. 
Methods: Tumor tissues and normal lung tissues were obtained by 
operation from 30 non-small cell lung cancer patients. Cancer cells 
and normal lung epithelium cells were cultured and saved as target 
cells. Total RNA were isolated and RT-PCR was done to determine 
XAGE-1b gene expression. XAGE-1b gene was cloned by constructing 
expression vector and recombinant protein was expressed and puri-
ﬁed by using BL21 (DE3) E. coli and AKTA-FPLC. Peripheral blood 
monocytes were isolated from 20ml blood and cultured to be DCs in 
serum-free DCs Medium. DCs were loaded with XAGE-1b protein 
through coculture and induced T lymphocytes into XAGE-1b-speciﬁc 
cytotoxic T lymphocytes (CTLs). The cytotoxicity of CTLs was then 
measured by cytotoxic assay. 
Results: 12/30(40%) lung cancer tissues expressed XAGE-1b gene, 
most of which were adenocarcinoma (11/12, 91.7%). None of normal 
tissues expressed it. Gene sequencing and western blot conﬁrmed the 
expression vector construction and recombinant protein expression. Im-
munoﬂuorescence identiﬁcation showed the accumulation of XAGE-1b 
protein in immature DCs. T lymphocytes were stimulated twice with 
XAGE-1b protein-loaded DCs. Cytotoxic assay showed that the CTL 
cytotoxicity was much stronger for XAGE-1b positive tumor cells than 
for XAGE-1b negative tumor cells and it was almost none for normal 
lung epithelium cells. 
Conclusions: Our study indicates that DCs loaded with XAGE-1b 
protein could induce speciﬁc antitumor effect against lung cancer cells 
in vitro and this model offers a new approach to the immunotherapy for 
lung cancer.
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Introduction: Lung cancer is a common malignancy worldwide with 
high morbidity and mortality. With increasing incidence of lung cancer 
world wide, there are few studies in Nigeria which have looked at the 
clinical and histological patterns of lung cancer in out center hence this 
study.
Method: We conducted a retrospective review of all cases of lung 
cancer seen at the National Hospital, Abuja, Nigeria over a 6 year 
period from 2001-2006. Cases were identiﬁed from the admission and 
discharge ﬁles on the wards and searched from the main record library 
.All cases which were retrieved were presented. Data were expressed 
using descriptive statiatics.
Results: Thirty two cases of Lung cancer were identiﬁed out of which 
sixteen cases were fully retrievable. These are presented in this study. 
The male to female ratio is 1.7:1 with a mean age of 55years (range 
from 40-85years). Smoking was the commonly identiﬁed risk factor 
which was present in 50% of the cases (7 males and 1 female).
Other identiﬁable potential risk factors were indoor and out door pol-
lution from burning biomass (18.7%), exposure to asbestos (12.5%). 
In 18.2% no risk factor could be identiﬁed.75% have a primary lung 
cancer of which adeno carcinoma was the commonest while secondar-
ies from breast, bone and cervical cancer was seen in the remaining 
25%. At presentation, 85% of the patients have developed extensive 
disease three patients with secondary lung cancer received combination 
chemotherapy and while radiotherapy with high dose steroid was given 
in those with SVO.
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Conclusion: Within the limits of retrospective analysis primary lung 
cancer is a more common form of lung cancer in this review.The com-
monest histological type being adenocarcinoma. 
Late presentation with extensive disease and a large diagnostic time 
was observed from admission to working up the patient and commenc-
ing treatment /death. 
There is a great need for training of physicians in diagnostic procedures 
and treatment of lung cancer in resource poor countries. Smoking either 
actively or passively should be discouraged. 
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Fiberoptic bronchoscopy as standard procedure in staging of 
carcinoma of the esophagus
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Fiberoptic bronchoscopy is standard endoscopic procedure in staging 
of carcinoma of the esophagus. In the bronchoscopy department of our 
Institute more than 3800 bronchoscopies are completed annualy. In the 
2005 to 2006 bronchoscopic staging of carcinoma of the esophagus was 
performed in 141 patients: 120 male 21 female. Normal endoscopic 
appearance existed in 105, direct signs of tumor in 21 and indirect signs 
in 14 patients. One patient had esophagobronchial ﬁstula. Inﬁltration 
of mucosa was established in 14, tumorous vegetation in 7 patients. 
In the group of patients with direct signs, squamocellular carcinoma 
was found in 13 patients. Localisation of direct signs of tumor: trachea 
in 7, main bronchi in 6 and lobar bronchi in 8 patients. Indirect signs 
were present in trachea in 8, main bronchi in 3 and lobar bronchi in 3 
patients. Fiberoptic bronchoscopy is inevitable diagnostic procedure 
in staging of esophageal cancer, which is safe, precise and easily ap-
plicable. It should be done in all patients with this malignancy. Indirect 
signs should be interpreted with caution, as some of them doesn’t 
contraindicate the operation
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Background: Pleurodesis is the treatment of choice for malignant 
pleural effusions. In study populations, talc seems to ensure effective 
pleurodesis in up to 95% of cases. However, data on patient selection, 
decision rules before and during the drainage procedure and effectivity 
score are not always included in published papers on pleurodesis. In the 
Netherlands, the national guideline “Malignant pleurisy”, published in 
2003, recommended e.g. to perform a diagnostic pleurocentesis before 
to proceed to pleurodesis and to perform a talc pleurodesis when the 
lung is completely aligned to the thoracic wall. In this study we mea-
sured the compliance to the guideline and the effectiveness of pleurode-
sis in current practice.
Methods: In four hospitals, all patients with (suspected) malignant 
pleurisy who were drained with the intention to perform a pleurodesis, 
were prospectively registrered. Diagnostic procedures, decision making 
during the drainage and outcome were monitored and compared to the 
guideline.
Results: We prospectively followed 100 patients from February 1st to 
November 30, 2006. All patients had a histologically or cytologically 
conﬁrmed malignancy. LDH, pH and protein levels in pleural ﬂuid 
were known in 84, 75 and 68% respectively before drainage or were 
determined during the procedure as recommended in the guideline. 
Malignant pleurisy was conﬁrmed cytologically in 58 patients, histo-
logically in 5 and was clinically suspected in 35 patients. In 75 patients 
a pleurodesis was performed. Reasons for not performing a pleurodesis 
were trapped lung in 15 patients, high ﬂuid production in 3, alternative 
diagnosis or unable to obtain a cytologic conﬁrmation of the diagnosis 
in 6 patients. Pleurodesis was performed with 2, 3 or 5 gr talc slurry at 
a median interval of 3 days (range 0 - 15 days) after start of the drain-
age. The drain was removed after 5 days (range 2 - 21 days) in case of 
pleurodesis and after 4 days (range 0-9 days) when no pleurodesis was 
performed. A recurrence of pleural ﬂuid was seen in 27 patients (36%), 
with a mean of 17 days after pleurodesis (range 2-285 days); in 11 
(14%) patients no radiological follow up was performed; 14 out of 44 
patients who had pleurodesis and no documented recurrence of pleural 
ﬂuid died during follow up with a median survival of 61 days (range 13 
- 174 days). The most frequently reported side effect during drainage 
was local pain. Ten late complications were reported: one empyema 
and one tumor growth into the scar of the drain were the most severe.
Conclusions: Compared to literature data, pleurodesis seems con-
siderably less effective in general practice. Parameters predicting the 
success rate of pleurodesis are not always known and do not affect 
clinical decision making. Future studies should focus on proper selec-
tion of patients for drainage and pleurodesis. Guidelines should also 
include alternative treatment options such as chronic indwelling pleural 
catheters.
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Bevacizumab is the ﬁrst anti-angiogenic agent inhibiting vascular 
endothelial growth factor (VEGF) for treatment of patients suffering 
from cancer. Life-threatening hemoptysis is the most serious adverse 
effect of bevacizumab. The inhibition of VEGF is a possible mecha-
nism involved in the destruction of normal lung tissue and subsequent 
hemoptysis. We report a case of bevacizumab-related hemoptysis and 
associated bronchoscopic ﬁndings that were successfully treated with 
rigid bronchoscopy and laser photocoagulation.
